First-in-Human cancer pill tested for advanced tumors
NCT ID NCT03449381
Summary
This early-stage study tested a new cancer pill called brigimadlin in adults with advanced solid tumors that had spread or couldn't be treated with standard options. Researchers aimed to find the highest safe dose patients could tolerate, then used that dose to see if the medication could shrink tumors. Participants took the tablets on specific schedules and stayed in the study as long as they benefited and could handle the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Florida Cancer Specialists-Sarasota-61670
Sarasota, Florida, 34232, United States
-
Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Helios Klinikum Berlin-Buch
Berlin, 13125, Germany
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Clínico de Santiago
Santiago de Compostela, 15706, Spain
-
Hospital Universitari Vall D Hebron
Barcelona, 08035, Spain
-
Karolinska Comprehensive Cancer Center
Stockholm, 171 76, Sweden
-
MED POLONIA SP Z O O, Clinical Trials Department,Poznan
Poznan, 60-693, Poland
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
Norton Cancer Institute, Downtown
Louisville, Kentucky, 40202, United States
-
Oncology Center-Maria Sklodowska-Curie Institute
Warsaw, 02-781, Poland
-
Rigshospitalet, København
København Ø, 2100, Denmark
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
Severance Hospital
Seoul, 03722, South Korea
-
Sourasky Medical Center
Tel Aviv, 6423906, Israel
-
The Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UZ Leuven
Leuven, 3000, Belgium
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Universitätsklinikum Köln (AöR)
Cologne, 50937, Germany
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
-
Universitätsmedizin Göttingen, Georg-August-Universität
Göttingen, 37075, Germany
-
Yale University School of Medicine
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.